Entellus Medical Inc (NASDAQ:ENTL) insider Robert S. White sold 3,471 shares of the business’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $24.01, for a total transaction of $83,338.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Entellus Medical Inc (NASDAQ ENTL) opened at $24.28 on Wednesday. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32. Entellus Medical Inc has a 1 year low of $11.47 and a 1 year high of $25.58. The stock has a market cap of $618.51 and a price-to-earnings ratio of -18.97.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Archon Capital Management LLC increased its holdings in shares of Entellus Medical by 14.9% in the third quarter. Archon Capital Management LLC now owns 550,224 shares of the medical technology company’s stock valued at $10,157,000 after purchasing an additional 71,404 shares during the last quarter. Aisling Capital LLC acquired a new position in shares of Entellus Medical in the third quarter valued at $9,759,000. First Light Asset Management LLC increased its holdings in shares of Entellus Medical by 25.7% in the second quarter. First Light Asset Management LLC now owns 512,416 shares of the medical technology company’s stock valued at $8,486,000 after purchasing an additional 104,919 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Entellus Medical by 14.2% in the second quarter. Vanguard Group Inc. now owns 485,294 shares of the medical technology company’s stock valued at $8,036,000 after purchasing an additional 60,471 shares during the last quarter. Finally, Tekla Capital Management LLC acquired a new position in shares of Entellus Medical in the second quarter valued at $5,655,000. 78.76% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have issued reports on ENTL shares. Canaccord Genuity reaffirmed a “hold” rating and set a $17.00 price target on shares of Entellus Medical in a research report on Tuesday, October 17th. Zacks Investment Research raised shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Monday, October 9th. TheStreet raised shares of Entellus Medical from a “d” rating to a “c-” rating in a research report on Thursday, December 14th. ValuEngine raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, William Blair lowered shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, December 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $19.25.

COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.watchlistnews.com/entellus-medical-inc-entl-insider-sells-83338-71-in-stock/1801019.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.